Approved & therapeutic
Micafungin
Mycamine
Micafungin is an echinocandin antifungal approved for candidaemia, oesophageal candidiasis and for prophylaxis of Candida infection in haematopoietic stem cell transplant recipients.
Also known as: FK463
- Status
- Micafungin is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- Approximately 14 to 17 hours.
- How it's taken
- Intravenous infusion
- Mechanism
- Immune modulation
How Micafungin works
Like other echinocandins, micafungin inhibits beta-(1,3)-D-glucan synthase, preventing synthesis of an essential fungal cell wall polysaccharide with no mammalian counterpart.
What research has looked at
- Fungicidal against Candida including fluconazole-resistant species.
- It requires no loading dose and no dose adjustment for renal impairment or for mild-to-moderate hepatic impairment.
- It has fewer drug interactions than caspofungin, as it is not a significant CYP3A4 substrate or inhibitor.
- Approved for prophylaxis in stem cell transplantation, a setting where interaction burden matters considerably.
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- The same tissue penetration limitations as the class: inadequate for urinary, central nervous system and intraocular candidiasis.
- Elevated liver enzymes, and rare reports of significant hepatic injury.
- Haemolysis and haemolytic anaemia have been reported.
- Infusion-related histamine reactions.
- Intravenous administration only.
Sources
- FDA approved-drug listing for micafungin · U.S. Food & Drug Administration
- DailyMed prescribing information for micafungin · NIH · DailyMed
- PubMed research on micafungin candidaemia prophylaxis · NIH · National Library of Medicine
- DrugBank record for micafungin · DrugBank
Track Micafungin in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Micafungin FAQ
What is Micafungin?
Micafungin is an echinocandin antifungal approved for candidaemia, oesophageal candidiasis and for prophylaxis of Candida infection in haematopoietic stem cell transplant recipients.
How does Micafungin work?
Like other echinocandins, micafungin inhibits beta-(1,3)-D-glucan synthase, preventing synthesis of an essential fungal cell wall polysaccharide with no mammalian counterpart.
Is Micafungin FDA approved?
Yes. Micafungin is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Micafungin?
Reported half-life: Approximately 14 to 17 hours.
How is Micafungin taken?
Intravenous infusion.
What side effects have been reported with Micafungin?
Reported in the sources: The same tissue penetration limitations as the class: inadequate for urinary, central nervous system and intraocular candidiasis; Elevated liver enzymes, and rare reports of significant hepatic injury; Haemolysis and haemolytic anaemia have been reported; Infusion-related histamine reactions; Intravenous administration only.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.